ABSTRACT

This invention provides smooth muscle cell proliferation inhibitors of formula I having the structure



I

wherein

R^1, R^2, R^3, R^4, R^5, R^6, R^7, and R^8 are each, independently, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, benzoyl, or $-SO_3H$;

R^9 is hydrogen, CN, NO_2, halo, CF_3, alkyl of 1-6 carbon atoms, or alkoxy of 1-6 carbon atoms;

R^{10} is hydrogen, $-NO_2$, $-NHR^{11}$, $-NHR^{13}$, $-N(R^{13})_2$, $-NCH_3R^{13}$, $-NHCO_2$alkyl, wherein the alkyl moiety contains 1-6 carbon atoms, alkylsulfonamide of 1 to 4 carbon atoms,



;

Z is O or S;

R^{11} is an α-amino acid in which the α carboxyl group forms an amide with the nitrogen of R^{10}, wherein if said amino acid is glutamic acid or aspartic acid, the non-α carboxylic acid is an alkyl ester in which the alkyl moiety contains from 1-6 carbon atoms;

R^{12} is hydrogen, CN, NO_2, halo, CF_3, alkyl of 1-6 carbon atoms, alkoxy of 1-6 carbon atoms, acyl of 2-7 carbon atoms, or benzoyl;

R^{13} is hydrogen, acyl of 2-7 carbon atoms, haloacyl of 2-7 carbon atoms, nitroacyl of 2-7 carbon atoms, cyanoacyl of 2-7 carbon atoms, trifluoromethylacyl of 3-8 carbon atoms, or benzoyl;

or a pharmaceutically acceptable salt thereof.

5